Feravir-200 (Favipiravir) 200 mg
Feravir-200 (Favipiravir 200 mg) is a broad-spectrum oral antiviral medication.
Manufacturer: Xenon Pharma (India). Originally developed for influenza, it has been repurposed globally for the treatment of mild to moderate COVID-19 infections.
Mechanism of Action ("Replication Blockade"):
Favipiravir is a selective inhibitor of viral RNA-dependent RNA polymerase. Simply put, it sabotages the virus's ability to copy its genetic material. By introducing errors into the viral RNA during replication, it prevents the virus from multiplying effectively, halting the spread of infection within the body.
✅ Key Benefit: Rapid reduction of viral load and faster clinical recovery.
Approved indications may vary by country, but generally include:
- 🦠 COVID-19: Mild to moderate coronavirus disease in adults.
- 🤧 Influenza: Novel or re-emerging influenza viruses (restricted to cases where other antivirals are ineffective).
Packaging: 200 mg Tablets.
⚠️ DOSING PROTOCOL (Typical):
- Requires a Loading Dose on Day 1 followed by a Maintenance Dose.
- 📅 Day 1: High dose (e.g., 1800 mg twice daily) to reach therapeutic levels quickly.
- 📅 Day 2 onwards: Lower dose (e.g., 800 mg twice daily).
- ⏳ Duration: Typically 7 to 14 days. Must be prescribed by a physician.
- 🤰 Pregnancy: STRICTLY CONTRAINDICATED. It has known teratogenic effects (causes birth defects).
- Both men and women must use effective contraception during and for a period after treatment.
- Severe renal or hepatic impairment.
- Hypersensitivity to Favipiravir.
Common adverse events include:
- 🧪 Hyperuricemia: Increased blood uric acid levels (most common).
- 🤢 Gastrointestinal: Diarrhea, nausea, vomiting.
- 🧬 Liver Enzymes: Elevated ALT/AST levels.
- Neutropenia (low white blood cell count).
What Customers Say
No reviews yet
Your review can be the first!